Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial - Prochaska, Jürgen H.; Jünger, Claus; Schulz, Andreas; Arnold, Natalie; Müller, Felix; Heidorn, Marc William; Baumkötter, Rieke; Zahn, Daniela; Koeck, Thomas; Tröbs, Sven-Oliver; Lackner, Karl J.; Daiber, Andreas; et al. (Clinical research in cardiology, 2023)
Keywords: Aged; Antidiabetics; Blood pressure; Body weight; Cardiology; Congestive heart failure; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Diastolic pressure; Double-Blind Method; Double-blind studies; Ejection fraction; Erythrocytes; Female; Glucose transporter; Heart failure; Heart Failure - complications; Heart Failure - diagnosis; Heart Failure - drug therapy; Hematocrit; Hemoglobin; Humans; Male; Mathematical analysis; Medicine; Medicine & Public Health; Middle Aged; NCT; NCT02932436; Original Paper; Placebos; Pressure effects; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Stroke Volume; Subgroups; Treatment Outcome; Uric acid; Ventricle; Ventricular Function, Left; Heart failure; Diastolic function; Biomarkers; Clinical trial; Type 2 diabetes mellitus